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Angiotensin II Induces Neutrophil Accumulation In Vivo
Through Generation and Release of CXC Chemokines
Yafa Naim Abu Nabah, BPharm*; Teresa Mateo, BPharm*; Rossana Estellés, BPharm, PhD;
Manuel Mata, BSc, PhD; John Zagorski, BSc, PhD; Henry Sarau, BSc, PhD;
Julio Cortijo, BPharm, PhD; Esteban J. Morcillo, MD, PhD; Peter J. Jose, BSc, PhD;
Maria-Jesus Sanz, BPharm, PhD
Background—Angiotensin II (Ang II) is implicated in the development of cardiac ischemic disorders in which prominent
neutrophil accumulation occurs. Ang II can be generated intravascularly by the renin-angiotensin system or
extravascularly by mast cell chymase. In this study, we characterized the ability of Ang II to induce neutrophil
accumulation.
Methods and Results—Intraperitoneal administration of Ang II (1 nmol/L) induced significant neutrophil recruitment
within 4 hours (13.32.3106 neutrophils per rat versus 0.70.5106 in control animals), which disappeared by 24
hours. Maximal levels of CXC chemokines were detected 1 hour after Ang II injection (577224 pmol/L
cytokine-inducible neutrophil chemoattractant [CINC]/keratinocyte-derived chemokine [KC] versus 53, and 281120
pmol/L macrophage inflammatory protein [MIP-2] versus 146). Intravital microscopy within the rat mesenteric
microcirculation showed that the short-term (30 to 60 minutes) leukocyte–endothelial cell interactions induced by Ang
II were attenuated by an anti-rat CINC/KC antibody and nearly abolished by the CXCR2 antagonist SB-517785-M. In
human umbilical vein endothelial cells (HUVECs) or human pulmonary artery media in culture, Ang II induced
interleukin (IL)-8 mRNA expression at 1, 4, and 24 hours and the release of IL-8 at 4 hours through interaction with
Ang II type 1 receptors. When HUVECs were pretreated with IL-1 for 24 hours to promote IL-8 storage in
Weibel-Palade bodies, the Ang II–induced IL-8 release was more rapid and of greater magnitude.
Conclusions—Ang II provokes rapid neutrophil recruitment, mediated through the release of CXC chemokines such as
CINC/KC and MIP-2 in rats and IL-8 in humans, and may contribute to the infiltration of neutrophils observed in acute
myocardial infarction. (Circulation. 2004;110:3581-3586.)
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Adirect and continuous relation between blood pressureand the incidence of various cardiovascular events, such
as stroke and myocardial infarction, is well accepted. Acti-
vation of the renin-angiotensin system has been demonstrated
in myocardial ischemia, acute myocardial infarction, and
coronary occlusion and reperfusion models, as well as in
chronic left ventricular dysfunction after myocardial infarc-
tion.1–3 Angiotensin II (Ang II) is the main effector peptide of
the renin-angiotensin system and can also be generated
extravascularly by the action of mast cell chymase.4 In
addition to its role as a potent vasoconstrictor and blood
pressure and fluid homeostasis regulator, Ang II has been
shown to exert proinflammatory activity. An indirect effect of
Ang II is suggested by the release of a neutrophil chemoat-
tractant, characterized only as a lipoxygenase metabolite of
arachidonic acid, from cultures of arterial endothelial cells.5
Furthermore, neutrophils express Ang II receptors,6 and
angiotensin-converting enzyme inhibition attenuates postis-
chemic adhesion of neutrophils in isolated, perfused hearts.7
Inflammation associated with acute myocardial infarction
is frequently marked by peripheral leukocytosis and relative
neutrophilia.8 Neutrophils infiltrate the postischemic myocar-
dium and cause much of the myocardial dysfunction associ-
ated with this condition.9–12 Therefore, much emphasis has
been placed on preventing neutrophil recruitment in an
attempt to minimize myocardial injury. The CXC chemokine
interleukin (IL)-8 has a crucial role in recruiting neutrophils
to the ischemic and reperfused myocardium.13 Whereas many
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cell types can synthesize IL-8, endothelial cells have the
additional capacity to store this chemokine in Weibel-Palade
bodies, together with von Willebrand factor and P-selectin.14
We have previously demonstrated that Ang II induces leuko-
cyte recruitment in postcapillary venules and that this re-
sponse is dependent on the increased expression of P-selectin
on the endothelial surface.15
Despite these studies, there have been no direct investiga-
tions into the ability of Ang II to induce neutrophil accumu-
lation in vivo. Therefore, the present study focused on the
potential of Ang II to mediate neutrophil accumulation in
vivo and the mechanisms involved in this response.
Methods
Materials
Ang II, histamine, cycloheximide, and PD123,319 were purchased
from Sigma Chemical Co; endothelial basal medium (EBM)-2
supplemented with endothelial growth media (EGM)-2 was from
Innogenetics; N,N,-[1,2-ethanediylbis(oxy-2,1-phenylene)]bis[N-
[2-[(acetyloxy)methoxy]-2-oxoethyl]]-, bis[(acetyloxy)methyl] ester
(Glycine; BAPTA-AM) was from Molecular Probes; human IL-8
and IL-1, rat cytokine-inducible neutrophil chemoattractant
(CINC)/keratinocyte-derived chemokine (KC) and macrophage in-
flammatory protein (MIP-2), and antibodies to rat CINC/KC and
MIP-2 were from PeproTech; the antibody pair for the human IL-8
ELISA was from R&D Systems; neutravidin–horseradish peroxi-
dase was from Perbio Science; the K-Blue substrate was from
Neogen; Dulbecco’s modified Eagle’s medium and TRIzol were
from Life Technologies; and the TaqMan predevelopment and
reverse transcription (RT) reagents were from PE Biosystems.
Losartan was donated by Merck Sharp & Dohme, Madrid, Spain.
The neutralizing anti-rat CINC/KC antibody was obtained as previ-
ously described.19 SB-517785-M was donated by GlaxoSmithKline.
Neutrophil Migration Into the Peritoneal Cavity
Sprague-Dawley rats (200 g to 250 g; Charles River, Barcelona,
Spain) were sedated with ether and injected intraperitoneally with 5
mL phosphate-buffered saline (PBS) or 1 nmol/L Ang II. After 1, 4,
8, or 24 hours, the rats were killed with an overdose of anesthetic,
and the peritoneal cavity was first lavaged with 5 mL PBS and then
with 30 mL heparinized (10 U/mL) PBS. The exudates were
centrifuged separately to obtain cell pellets and supernatant fluids.
The cell pellets were combined for total leukocyte counts in a
hemocytometer and differential cell analysis of 500 cells per slide on
cytospins stained with May-Grünwald and Giemsa stains. Results are
expressed as the number of neutrophils recovered from each cavity.
The supernatant from the first (5-mL) lavage was used for determi-
nation of total protein content by the Bradford method and, after
addition of carrier protein (0.5% bovine serum albumin) and storage
at 20°C, for determination of inflammatory mediator concentra-
tions. All procedures were approved by the institutional ethics
committee.
Intravital Microscopy
Experimental details have been described previously.15 In brief, male
Sprague-Dawley rats (body weight, 200 to 250 g) were anesthetized
with sodium pentobarbital (65 mg/kg IP). A segment of the midje-
junum was exteriorized and placed over an optically clear viewing
pedestal maintained at 37°C. The exposed mesentery was continu-
ously superfused with warmed bicarbonate-buffered saline, pH 7.4.
An orthostatic microscope (Nikon Optiphot-2, SMZ1) equipped with
a 20 objective lens (Nikon SLDW) and a 10 eyepiece allowed
tissue visualization. Single, unbranched, mesenteric venules were
selected, and the diameters (25 to 40 m) were measured online with
use of a video caliper (Microcirculation Research Institute, Texas
A&M University, College Station, Tex). Centerline red blood cell
velocity was also measured online with an optical Doppler velocim-
eter (Microcirculation Research Institute). A video camera (Sony
SSC-C350P) mounted on the microscope projected images onto a
color monitor (Sony Trinitron PVM-14N2E), and these images were
captured on videotape (Sony SVT-S3000P) for playback analysis
(final magnification, 1300) of the number of rolling, adherent, and
emigrated leukocytes. Venular blood flow and wall shear rate were
calculated as previously described.16
Experimental Protocol
All preparations were left to stabilize for 30 minutes, and baseline
(time 0) measurements of leukocyte rolling flux and velocity,
leukocyte adhesion, leukocyte emigration, mean arterial blood pres-
sure, centerline red blood cell velocity, shear rate, and venular
diameter were obtained. The superfusion buffer was either continued
or supplemented with 1 nmol/L Ang II. Recordings were performed
for 5 minutes at 15-minute intervals for 60 minutes, and the
aforementioned leukocyte and hemodynamic parameters were mea-
sured. Some animals were pretreated with a polyclonal antibody
against rat CINC/KC (10 mg/kg IV at 15 minutes) or with a
selective CXCR2 receptor antagonist (SB-517785-M, 25 mg/kg PO
at 60 minutes) before Ang II superfusion.
Cell Culture
Human umbilical endothelial cells (HUVECs) were isolated by
collagenase treatment17 and maintained in human endothelial cell–
specific EBM-2 supplemented with EGM-2 and 10% fetal calf serum
(FCS). HUVECs up to passage 2 were grown to confluence on
24-well culture plates. Before every experiment, cells were incubated
for 16 hours in medium containing 1% FCS and then returned to the
10% FCS medium for all experimental incubations. Human pulmo-
nary arteries were obtained from patients undergoing lobectomy or
pneumonectomy from bronchial carcinoma. Studies were approved
by the institutional ethics committee. The arteries were opened; the
endothelial surface was removed by gentle scrapping with a scalpel;
the surrounding adventitia was carefully dissected away; and the
tunica media, cut into 3- to 5-mm sections, was placed on 24-well
culture plates in Dulbecco’s modified Eagle’ with 10% FCS.
Cells or human pulmonary artery media (HPAM) was stimulated
with 1 to 1000 nmol/L Ang II for 1, 4, 24, or 48 hours. Selective
antagonists of Ang II type 1 (AT1; losartan, 10 mol/L) or type 2
(PD123,319, 10 mol/L) receptors or a combination of both was
added to some wells 1 hour before Ang II (100 nmol/L). Where
stated, HUVECs were preincubated with IL-1 (1000 U/mL) for 24
hours to induce synthesis and storage of IL-8 in Weibel-Palade
bodies,14 washed twice, and incubated for 1 hour in fresh medium
with or without 1 to 1000 nmol/L Ang II or 100 mol/L histamine
as the positive control. Cycloheximide (0.1 mg/mL) or BAPTA-AM
(100 mol/L) was added to some wells 1 hour before Ang II (100
nmol/L). At the end of the experiment, cell-free supernatants were
stored at 20°C for IL-8 ELISA, and HUVECs were washed before
digestion in 0.5 mol/L NaOH for determination of protein content by
the Lowry procedure or for weighing of the arterial media.
Quantitative RT-PCR
IL-8 mRNA was determined by real-time quantitative RT–poly-
merase chain reaction (PCR). HUVECs or HPAM was incubated
with medium or 100 nmol/L Ang II for 1, 4, or 24 hours, and total
RNA was extracted with TRIzol. Quantitative data of relative gene
expression were determined by the comparative Ct method (Ct),
as described by the manufacturer (PE-ABI PRISM 7700 sequence
detection system) and previously reported.18 Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was the endogenous control
gene. TaqMan predevelopment assay reagents were used to deter-
mine IL-8 mRNA, and TaqMan RT reagents were used to generate
cDNA.
Enzyme-Linked Immunosorbent Assays
Rat CINC/KC and MIP-2 levels were determined by conventional
sandwich ELISAs. Results are expressed as picomoles chemokine in
the supernatant from the 5-mL lavage. No cross-reactions were
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detected in the CINC/KC and MIP-2 assays with any rat chemokines
tested: regulated on activation normal T expressed and secreted,
monocyte chemoattractant protein-1, and MIP-2 or KC (0.01%).
Human IL-8 was measured in culture supernatants. The blocking
step was omitted as unnecessary in samples containing 10% FCS and
diluted in PBS/0.5% bovine serum albumin.
Statistical Analysis
All values are meanSEM. Data between groups were compared by
1-way ANOVA with a Newman-Keuls post hoc correction for
multiple comparisons. Statistical significance was set at P0.05.
Results
Intraperitoneal injection of 5 mL of 1 nmol/L Ang II in rats
induced a significant neutrophil recruitment that was maxi-
mal at 4 hours and had resolved by 24 hours (Figure 1A).
Total protein content in the peritoneal exudate was not
modified by Ang II administration at any of the times studied
(Figure 1B). CINC/KC and MIP-2 levels were elevated after
Ang II injection, peaking at 1 hour (Figure 1C and 1D) before
significant neutrophil infiltration was seen. Significant CXC
chemokine levels were still evident at 4 hours but had
declined to basal levels by 8 hours. This time course is
consistent with a contribution of the CXC chemokines to
neutrophil recruitment.
To investigate the mechanisms involved, Ang II–induced
responses were studied for 1 hour by intravital microscopy to
evaluate leukocyte rolling, adherence to the endothelium, and
emigration into the mesentery, events that would be expected
to precede leukocyte accumulation in the peritoneal cavity.
Figure 2. Effect of anti-rat CINC/KC anti-
body and CXCR2 antagonist on Ang
II–induced leukocyte rolling flux (A), roll-
ing velocity (B), adhesion (C), and emi-
gration (D) in rat mesenteric postcapillary
venules. Parameters were measured 0,
15, 30, and 60 minutes after superfusion
with buffer (n5) or with 1 nmol/L Ang II
in animals untreated (n7) or pretreated
with anti rat CINC/KC antibody (10
mg/kg IV, n9) or with CXCR2 antago-
nist (25 mg/kg PO, n5). Results are
meanSEM. *P0.05. **P0.01 relative
to values in buffer group. 	P0.05,
		P0.01 relative to untreated Ang II
group. Abbreviations are as defined in
text.
Figure 1. Time course of Ang II–induced
neutrophil accumulation (A), protein
extravasation (B), and CINC/KC (C) and
MIP-2 (D) generation. Rats were injected
intraperitoneally with 5 mL PBS or 1
nmol/L Ang II. Results are meanSEM
for n4 or 5 animals per group.
*P0.05, **P0.01 relative to values in
PBS-injected group. Abbreviations are as
defined in text.
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As shown in Figure 2, superfusion of the mesentery with 1
nmol/L Ang II induced a decrease in leukocyte rolling
velocity and increases in leukocyte rolling flux, adhesion, and
emigration within 30 minutes. Administration of a neutraliz-
ing anti-rat CINC/KC antibody inhibited the Ang II–induced
responses at 30 and 60 minutes, the inhibition of leukocyte
rolling flux, adhesion, and emigration at 60 minutes being
66%, 89%, and 67%, respectively (Figure 2). Because the
peritoneal exudate fluids contained MIP-2 in addition to
CINC/KC (Figure 1), we next used a CXCR2 antagonist that
is known to inhibit rat neutrophil responses to both chemo-
kines.20 Blockade of CXCR2 with SB-517785-M was more
effective than the antibody treatment, the inhibition of Ang
II–induced leukocyte rolling flux, adhesion, and emigration
responses at 60 minutes being 100%, 91%, and 100%,
respectively (Figure 2). Likewise, SB-517785-M treatment
returned the Ang II–induced decrease in leukocyte rolling
velocity to basal levels (Figure 2B). Neither the Ang II
superfusion nor the systemic anti-CINC/KC or SB-517785-M
pretreatments affected circulating leukocyte counts, mean
arterial blood pressure, or shear rate (Table).
To investigate Ang II–induced chemokine release at the
cellular level, we used cultures of HUVECs and HPAM. IL-8
mRNA was increased within 1 hour after stimulation with
100 nmol/L Ang II (Figure 3). IL-8 protein secretion in both
HUVECs and HPAM was unaffected in the first hour of
incubation with Ang II (data not shown) but was significantly
increased after 4 hours (Figure 4A HUVECs, 17941 and
24165 nmol/mg cellular protein at 100 and 1000 nmol/L
Ang II, respectively, versus 12921 in unstimulated cells;
Figure 4B HPAM, 4.491.19 and 6.811.59 nmol/mg tissue
at 100 and 1000 nmol/L Ang II, respectively, versus
1.330.38 in controls). These effects appear to be mediated
through interaction of Ang II with its AT1 receptor, because
losartan but not the type 2 receptor antagonist PD123,319
inhibited 100 nmol/L Ang II–induced IL-8 release (Figure 4).
IL-8 protein concentration was no higher at 24 and 48 hours
than at 4 hours. In contrast to many endothelial cells,
HUVECs have little preformed IL-8 stored in Weibel-Palade
bodies.14 To investigate the ability of Ang II to induce IL-8
release, HUVECs were pretreated with IL-1 to promote IL-8
storage14 and then incubated for 1 hour in fresh medium with
or without Ang II but without IL-1. Under these conditions,
Ang II caused a dose-dependent release of IL-8 that was
markedly higher (2689234 and 3327477 nmol/mg cellu-
lar protein with 100 and 1000 nmol/L Ang II, respectively)
than that seen without pretreatment; again, these effects were
AT1 receptor mediated (Figure 5). Pretreatment with the
protein synthesis inhibitor cycloheximide had no effect on the
amount of IL-8 released in response to Ang II. In contrast,
inhibition of Weibel-Palade body degranulation by pretreat-
ment with BAPTA-AM resulted in complete inhibition of
Ang II–induced IL-8 release (Figure 5).
Discussion
Activation of the renin-angiotensin system, including the
generation of Ang II, has been clearly demonstrated in several
Hemodynamic Parameters and Systemic Leukocyte Counts
Treatment
Mean Arterial Blood
Pressure, mm Hg Shear Rate, s1
Systemic Leukocyte
Counts, 106 Cells/mL
Buffer 103.29.7 588.174.1 10.90.7
Ang II, 1 nmol/L 110.011.6 714.461.7 9.80.6
Ang II	anti-CINC/KC antibody 115.77.4 701.673.7 10.61.0
Ang II	CXCR2 antagonist 120.63.9 667.688.7 11.41.1
Table summarizes hemodynamic parameters and systemic leukocyte counts in animals used for
intravital microscopy studies. Parameters were measured 60 minutes after superfusion with buffer
(n5) or with 1 nmol/L Ang II in animals untreated (n7), pretreated with an anti-rat CINC/KC
antibody (10 mg/kg IV, n9) or pretreated with a CXCR2 antagonist (25 mg/kg PO, n5). Results are
meanSEM. Abbreviations are as defined in text.
Figure 3. Time course of Ang II–induced IL-8 mRNA increase in
HUVECs (A) and HPAM (B). HUVECs or HPAM was stimulated
with 100 nmol/L Ang II or medium for 1, 4, or 24 hours. Total
mRNA was extracted. Relative quantification of mRNA levels of
IL-8 and GAPDH was determined by using real-time quantitative
RT-PCR by comparative Ct method (Ct method). Columns
show fold increase in expression of IL-8 mRNA relative to con-
trol GAPDH values, calculated as meanSEM of 2Ct values
of n4 experiments. **P0.01 relative to values in control
group. Abbreviations are as defined in text.
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inflammatory conditions, in particular in the heart. In the
present study, we show for the first time that Ang II can
induce rapid neutrophil infiltration in vivo, a finding that
might be relevant in acute myocardial infarction. To investi-
gate this possibility, we chose to inject Ang II into the
peritoneal cavity for 2 reasons. First, the neutrophils could be
unequivocally identified and measured by microscopy with-
out resort to measuring secondary markers such as myeloper-
oxidase activity or the use of labeled cells. Second, the
preceding events of rolling and adhesion to the endothelium
could be investigated in detail by intravital microscopy of the
mesenteric microcirculation. We established that Ang II
induces neutrophil accumulation that is preceded by the
generation of the neutrophil chemoattractant CXC chemo-
kines, CINC/KC and MIP-2. Accordingly, the early leukocy-
te–endothelial cell interactions were substantially inhibited
by neutralization of the activity of CINC/KC and almost
totally inhibited by blockade of CXCR2, the only high-
affinity receptor on rat neutrophils for CXC chemokines.20
Thus, although rat neutrophils possess Ang II receptors,6 our
results suggest an indirect mechanism by which the release of
CINC/KC, MIP-2, and possibly other CXC chemokines in
response to Ang II accounts for the majority of neutrophil
accumulation in this model.
The major CXC chemokine involved in human myocardial
inflammation is thought to be IL-8.13 Many cell types are
capable of producing this potent neutrophil chemoattractant.
We used HUVECs and fragments of HPAM, mainly com-
prising smooth muscle cells, and showed that Ang II induced
IL-8 mRNA synthesis within 1 hour and secretion of the
chemokine within 4 hours. This suggests a transcriptional
event in both cell types. In this context, inducible transcrip-
tion factors such as nuclear factor (NF)-IL-6, activator
protein-1, and NF-B promote IL-8 mRNA expression,21 and
Ang II can induce NF-B activation.22 However, the in vivo
data show a more rapid release of CXC chemokines, suggest-
ing a posttranslational event. To differentiate between de
novo synthesis and the release of stored IL-8, we took
advantage of the fact that HUVECs can be induced by IL-1 to
synthesize and store IL-8 so that they more closely resemble
adult endothelial cells.14 Under these conditions, the secretion
of IL-8 in response to Ang II was both more rapid and of
greater magnitude than in HUVECs not pretreated with IL-1.
The independence of these responses on protein synthesis
Figure 4. Effect of Ang II on IL-8 release in HUVECs (A) and
HPAM (B). HUVECs or HPAM was stimulated with Ang II (1 to
1000 nmol/L), 100 nmol/L Ang II	10 mol/L losartan, 	10
mol/L PD123,319, or combination of both antagonists for 4
hours. Release of IL-8 in response to Ang II is expressed as
percentage of that in medium control, meanSEM of n4 or 5
experiments. *P0.05, **P0.01 relative to values in medium
control group. 	P0.05, 		P0.01 relative to 100 nmol/L Ang
II. Abbreviations are as defined in text.
Figure 5. Effect of Ang II on IL-8 release in IL-1–stimulated
HUVECs. HUVECs were stimulated with 1000 U/mL IL-1 for 24
hours. Then cells were washed and further stimulated with Ang
II (1 to 1000 nmol/L), 100 nmol/L Ang II	10 mol/L losartan,
	10 mol/L PD123,319, combination of both antagonists,
cycloheximide, or BAPTA-AM for 1 hour. Histamine (100
mol/L) was used as positive control. Release of IL-8 in
response to Ang II is expressed as percentage of that in
medium control, meanSEM of n5 experiments. *P0.05,
**P0.01 relative to values in medium control group. 	P0.05 rel-
ative to 100 nmol/L Ang II. Abbreviations are as defined in text.
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strongly suggests the release of IL-8 from preformed stores
such as endothelial Weibel-Palade bodies. Accordingly, inhi-
bition of Weibel-Palade body degranulation with a calcium
chelator abolished the Ang II–induced IL-8 release. Thus, the
generation of Ang II at sites of inflammation could lead to
CXC chemokine release involving both a posttranslational
event, contributing to the initial phase of neutrophil infiltra-
tion, and a transcriptional event that may contribute to a more
sustained neutrophil recruitment.
Expression of IL-8 on the endothelial surface leads to rapid
neutrophil–endothelial cell interactions. Such interactions are
multistep processes that include P-selectin expression, lead-
ing to rolling of leukocytes on the endothelium.23 Like IL-8,
P-selectin is presynthesized and stored in endothelial cell
Weibel-Palade bodies14 and is rapidly mobilized to the cell
surface after exposure to Ang II.15 Because CXC chemokines
induce P-selectin upregulation,24 it is possible that the release
of IL-8 in response to Ang II augments the P-selectin
upregulation. Therefore, in addition to their role in Ang
II–induced neutrophil adhesion and migration, CXC chemo-
kines may also contribute to the rolling response elicited by
this peptide hormone. All of the responses described in this
study were inhibited by losartan but not PD123,319, suggest-
ing that the effects were mediated through interaction of Ang
II with its AT1 receptor. The Ang II concentrations required
to stimulate cells in culture were physiologically relevant, at
least for the arterial media, and similar to that used in the in
vivo studies. The rapid and transient effects of Ang II in vivo,
when compared with those detected in cell culture, may be
explained by the rapid metabolism of Ang II in vivo.
In conclusion, in this study we have demonstrated that Ang
II induces neutrophil accumulation in vivo via the secretion
of CXC chemokines, the source of which may include
endothelial cell Weibel-Palade bodies and vascular smooth
muscle cells, and this effect is mediated through interaction of
Ang II with its AT1 receptor. Ang II is formed from the
decapeptide Ang I by the action of a carboxydipeptidase,
angiotensin-converting enzyme, found on the endothelial cell
surface and in the plasma. An alternative source of Ang II
generation in the heart is mast cell chymase,4 which generates
Ang II directly from Ang I.4 Therefore, Ang II should be
considered a potential inflammatory mediator of neutrophil
infiltration observed in acute myocardial infarction through
the release of CXC chemokines, and CXC receptor antago-
nists may become a powerful tool in the control of inflam-
mation associated with acute myocardial infarction.
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